|Bid||4.590 x N/A|
|Ask||4.600 x N/A|
|Day's Range||4.390 - 4.650|
|52 Week Range||3.150 - 5.450|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.01 (0.23%)|
|1y Target Est||N/A|
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Viva Biotech Holdings...
During the Review Period, amid the boom of global patent drug market, Viva Biotech firmly seized the rising opportunities in the industry and realized significant growth leveraging on its world-leading structure-based early stage drug discovery platform. The Group's revenue recorded a significant increase of 83.9% to approximately RMB142.3 million compared with the same period last year, and the net profit excluding extraordinary profit or loss increased by 47.4% to approximately RMB98.6 million. Upholding the mission of becoming a cradle for promising biotechnology startups around the world, Viva Biotech has developed a scalable business model combining the conventional cash-for service (CFS) model and unique equity-for-service (EFS) model, under which the Group can effectively promote the development of biotech start-ups with promising prospects while maintaining stable cash inflows from CFS customers, and enjoy the rising potential of its intellectual property value.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...